The best online stock broker. Open an account today and start earning up to $1000 of IBKR Stock !
Monday, February 28, 2022
Sunday, February 27, 2022
The shares of our page with the best and worst performance of the week
IMPORTANT POSTS
BAYERN - GOLDEN CROSS
Hellenic Telecommunications: 52 week high
Saturday, February 26, 2022
Friday, February 25, 2022
Thursday, February 24, 2022
SAGE: F INANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2021
INANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2021
- Cash Position: Cash, cash equivalents and marketable securities as of
December 31, 2021 were$1.7 billion compared to$1.8 billion atSeptember 30, 2021 .
- Revenue: Net revenue from sales of ZULRESSO was
$1.6 million in the fourth quarter of 2021 compared to$1.7 million in the same period of 2020. For the year endedDecember 31, 2021 , net revenue from sales of ZULRESSO was$6.3 million compared to$6.7 million in the same period of 2020. Additionally, in the fourth quarter of 2020, Sage recorded$1.1 billion of collaboration revenue from Biogen that consisted of an upfront payment of$875 million plus$232.5 million in excess proceeds from the equity investment under the stock purchase agreement.
- R&D Expenses: Research and development expenses were
$75.4 million , including$9.1 million of non-cash stock-based compensation expense, in the fourth quarter of 2021 compared to$81.7 million , including$10.1 million of non-cash stock-based compensation expense, for the same period in 2020. For the year endedDecember 31, 2021 , R&D expenses were$283.2 million , including$49.7 million of non-cash stock-based compensation expense, compared to$292.7 million , including$42.4 million of non-cash stock-based compensation expense, for the same period in 2020. For the year, the decrease in R&D expenses was primarily due to the reimbursement from Biogen of$79.8 million pursuant to the Sage/Biogen Collaboration and License Agreement, partially offset by an increase in spending of$70.3 million . The increase in spending was mainly attributable to increased spending on zuranolone and Sage’s wholly owned pipeline including SAGE-718 and other programs. For the year, non-cash stock-based compensation expense increased because the Company incurred$9.8 million of expense in 2021 due to the achievement of milestones for certain outstanding performance restricted stock units and incurred no expense for such grants in 2020.
- SG&A Expenses: Selling, general and administrative expenses were
$51.6 million , including$11.5 million of non-cash stock-based compensation expense, in the fourth quarter of 2021 compared to$53.5 million , including$10.6 million of non-cash stock-based compensation expense, for the same period in 2020. For the year endedDecember 31, 2021 , SG&A expenses were$183.5 million , including$54.9 million of non-cash stock-based compensation expense, compared to$197.0 million , including$51.8 million of non-cash stock-based compensation expense, for the same period in 2020. For the year, the decrease in SG&A expenses was primarily due to the reimbursement from Biogen of$11.3 million pursuant to the Sage/Biogen Collaboration and License Agreement, along with the impact of the restructuring that the Company announced during the second quarter of 2020. For the year, non-cash stock-based compensation expense increased because the Company incurred$6.7 million of expense in 2021 due to the achievement of milestones for certain outstanding performance restricted stock units and incurred no expense for such grants in 2020.
- Net Income (loss): Net loss was
$124.7 million for the fourth quarter of 2021 compared to net income of$974.9 million for the same period in 2020. For the year endedDecember 31, 2021 , net loss was$457.9 million compared to net income of$606.1 million for the same period in 2020. In both periods, the decrease was due to the collaboration revenue from Biogen.
FINANCIAL GUIDANCE
- Sage anticipates cash, cash equivalents and marketable securities of approximately
$1.3 billion at the end of 2022. - The Company does not anticipate receipt of any milestone payments from collaborations in 2022.
- The Company believes its cash and cash equivalents, ongoing collaboration funding, and potential revenue, will support its operations into 2025.
Conference Call Information
Sage will host a conference call and webcast today,
About
Wednesday, February 23, 2022
Tuesday, February 22, 2022
Monday, February 21, 2022
Sunday, February 20, 2022
The shares of our page with the best and worst performance of the week
The financial and technical analycies presented on this website have not been performed by an Investment Services Company, nor have they been compiled by a certified analyst . It is simply a display and presentation of public data of Greek and foreign shares with informative and entertaining character.
BioDelivery Sciences International (BDSI.NASDAQ)
Public Proposal - (COLLEGIUM)
Public Proposal (ALLIANZ)
Thessaloniki Port Authority Societe Anonyme(ATHEX)
Boston Beer Company Inc (SAM.NYSE)
IMPORTANT POSTS
Warren Buffett: How To Make Millions From Huge Crash Ahead
Saturday, February 19, 2022
Warren Buffett: How To Make Millions From Huge Crash Ahead
Warren Buffett: How To Make Millions From Huge Crash Ahead
Friday, February 18, 2022
TERNA ENERGY: The amendment of the Public-Private Partnership (PPP) Agreement for the Integrated Waste Management of Peloponnese Region was signed
The amendment of the Public-Private Partnership (PPP) Agreement for the Integrated Waste Management of Peloponnese Region was signed
The modern, socially responsible and fully integrated waste management in the Peloponnese Region, Greece, becomes a reality as of today, following the relevant amendment of the Public-Private Partnership (PPP) Agreement for the Integrated Waste Management of this region, signed between the Peloponnese Region Authority and the entity “Perivallontiki of Peloponnese’’, member of TERNA ENERGY Group.
The signing of the amended Partnership Agreement facilitates the Intermediate Waste Management period in the units of the project that have already been completed (Transitional Waste Management Unit in Paleochouni, County of Arcadia and Waste Transfer Station in Nea Kios, County of Argolida), providing modern waste management services with the environmental protection as core priority and ensuring that public health requirements are met, offering at the same time multiple benefits to local communities which function as vital parts of the circular economy.
Alphabet Announces Fourth Quarter and Fiscal Year 2021 Results more
Alphabet Announces Fourth Quarter and Fiscal Year 2021 Results more
Bayer raises peak sales for Nubeqa to exceed three billion euro amid positive Phase III ARASENS trial data
|
|---|
|
|---|
Thessaloniki Port Authority Societe Anonyme EBITDA €
Thessaloniki Port Authority Societe Anonyme EBITDA €
Thursday, February 17, 2022
OPAP: the VALEA FOUNDATION, and the entities controlled by, and acting in concert with, VALEA FOUNDATION and following SAZKA Group a.s.’ acquisitions from the market since 16 December 2021, indirectly control in total 48.09% of the total share capital and voting rights in OPAP
17/02/2022
SAZKA Entertainment AG operating under the brand name Allwyn (“Allwyn”) today announced that RUBIDIUM HOLDINGS LIMITED (“Rubidium”) through which Allwyn indirectly holds non-voting shares of OPAP S.A. (“OPAP”) reached an agreement with Yeonama Holdings Co. Limited (“Yeonama”) to purchase the remaining minority non-voting shares of Yeonama in SAZKA Delta AIF Variable Investment Company Ltd (“SAZKA Delta”), an entity through which Allwyn holds part of its interest in OPAP for consideration of €327.4 million (the “Transaction”). As a result, Allwyn’s economic interest (i.e. the percentage representing, regardless of control of SAZKA Delta, the participation in distributions but not the voting rights) in OPAP will increase from approximately 41.2% to approximately 48.1%. It is reminded that reference to the non-voting shares held by Yeonama was made in the Information Memorandum in relation to the voluntary tender offer launched by SAZKA Group a.s., which has been approved by the HCMC on 30 September 2019.
Taking into account the net debt and working capital of SAZKA Delta, the Transaction implies a premium of more than 10% on OPAP’s current market share price. The purchase price will be financed with cash from the balance sheet, including cash raised by the recent €600 million bond issuance.
The Transaction has no impact on the sole control exercised by VALEA FOUNDATION over SAZKA Delta, and thus no impact on the number and percentage of shares and voting rights in OPAP indirectly controlled by VALEA FOUNDATION and the entities controlled by, and acting in concert with, VALEA FOUNDATION within the meaning of Law 3556/2007, which according to latest TR-1 notification by VALEA FOUNDATION dated 7 January 2022 was equal to 47.13% as of 16 December 2021.
As of today the VALEA FOUNDATION, and the entities controlled by, and acting in concert with, VALEA FOUNDATION and following SAZKA Group a.s.’ acquisitions from the market since 16 December 2021, indirectly control in total 48.09% of the total share capital and voting rights in OPAP, as follows:
Corporate Name
Percentage
VALEA FOUNDATION
48.09
Valea Holding AG
48.09
KKCG Holding AG
48.09
KKCG AG
48.09
SAZKA Entertainment AG
48.09
SAZKA Group a.s.
48.09
Sazka Delta Management Ltd. (formerly Emma Delta Management Ltd.)
48.09
SAZKA Delta AIF Variable Capital Investment Company Ltd. (formerly Emma Delta Variable Capital Investment Company Ltd.)
48.09
SAZKA Delta Hellenic Holdings Limited (formerly Emma Delta Hellenic Holdings Limited)
48.09
Bayer highlights advancements of agriculture industry’s most prolific R&D pipeline
Crop Science R&D Pipeline Update 2022
Bayer highlights advancements of agriculture industry’s most prolific R&D pipelineIndustry-leading investment expected to translate to nearly €30bn peak sales potential / Game-changing Short Stature Corn advances, readying for 2023 commercial trials / More than 500 new high-performing seed hybrids and varieties deployed and greater than 300 new registrations refresh crop protection portfolio / Digital transformation well underway as Climate FieldView™ reaches more than 180 million acres; unlocks climate-smart models with expansion of Bayer Carbon Initiative
Bayer showcases the latest in crop protection, seeds & traits and digital solutions. ...
Wednesday, February 16, 2022
Thessaloniki Port Authority Societe Anonyme REVENUE €
Thessaloniki Port Authority Societe Anonyme REVENUE €
Tuesday, February 15, 2022
Monday, February 14, 2022
BDSI 52 WEEK HIGH
BioDelivery Sciences International (BDSI) 52 WEEK HIGH
Collegium Pharma Broadens Its Pain Portfolio With $600M BioDelivery Sciences Deal
Collegium Pharmaceutical Inc (NASDAQ: COLL) will acquire BioDelivery Sciences International Inc (NASDAQ: BDSI) at $5.60 per share in an all-cash transaction...
Thessaloniki Port Authority Societe Anonyme(ATHEX)-Dividends
Thessaloniki Port Authority Societe Anonyme(ATHEX)-Dividends
Sunday, February 13, 2022
The shares of our page with the best and worst performance of the week
Corsair Gaming, Inc.
FREEDOME 24
After opening an account, you will receive a free share worth up to $ 600
COMPANY OF THE WEEK: Mytilineos (MYTIL.AT)
European Reliance: ANNOUNCEMENT FOR IMPORTANT EVENTS
ANNOUNCEMENT FOR IMPORTANT EVENTS
Today, the Offeror executed share purchase agreements with Company’s shareholders for the acquisition of 19.181.256 shares before the end of the Tender Offer Acceptance Period, which represent in total 72,2% of the shares and voting rights in the Company, subject to approvals required by the competent regulatory authorities, the Bank of Greece, the Hellenic Capital Market Commission and the Hellenic Competition Commission (hereinafter the Transaction). In particular the Offeror has executed share purchase agreements with the following:
1. shareholders of the Company, including Company’s executives and the CEO, for the acquisition of 5.313.400 shares representing 20.02% of shares and voting rights in the Company;
2. EBRD, for the acquisition of 4.125.552 shares representing 15.54% of shares and voting rights in the Company; and
3. other shareholders, for the acquisition of 9.742.304 shares representing 36.7% of shares and voting rights in the Company.
The long term plans of the Offeror include the integration of Company's activities with those of the Allianz Group's subsidiary in Greece with Mr. Christos Georgakopoulos as CEO, the promotion of the Company's brands and the strengthening of the Allianz Group’s role in the Greek insurance market.
The proposed participation of the Offeror in the Company's share capital and the fact that Mr. Christos Georgakopoulos shall remain in the Company's management will ensure the continuation of the Company's business strategy and operation under the same successful business principles, but will also result in achieving additional benefits which will arise from the Company's participation in a global group operating in the same sector, thus contributing to the further strengthening of the Company's position in the market.
Alphacap acts as financial advisor and law firm Zepos & Yannopoulos acts as legal advisor in relation to the Transaction.
Friday, February 11, 2022
European Reliance 52 week high
Allianz close to an agreement for the acquisition of European Reliance
Thursday, February 10, 2022
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049) - NET DEBT
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049) - NET DEBT
Wednesday, February 9, 2022
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049) - Revenue
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049) - Revenue
Sunday, February 6, 2022
Saturday, February 5, 2022
MYTILINEOS S.A. (MYTIL:ATH) ΤΟΤΑL DEBT VS TOTAL CASH €
MYTILINEOS S.A. (MYTIL:ATH) ΤΟΤΑL DEBT VS TOTAL CASH €
Friday, February 4, 2022
Bayer will discontinue phase II development candidate eliapixant
Bayer will discontinue phase II development candidate eliapixantReview of development program led to reassessment of benefit-risk ratio in all four potential indications for the investigational P2X3 receptor antagonist
Berlin, Germany, February 4, 2022 – Bayer today announced the discontinuation of Phase II development candidate eliapixant (BAY 1817080), an investigational P2X3 receptor antagonist that was being evaluated for potential indications in endometriosis, refractory chronic cough, overactive bladder and diabetic neuropathic pain. Following a review of available data, Bayer concluded that the overall benefit no longer outweighs the risk in these indications.
Eliapixant is an investigational agent and has not been approved for use in any country, for any indication.
Thursday, February 3, 2022
Wednesday, February 2, 2022
Subscribe to:
Posts (Atom)